{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:13Z","timestamp":1791899473821,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jsat.2022.108921","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T21:47:57Z","timestamp":1666820877000},"page":"108921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder"],"prefix":"10.1016","volume":"144","author":[{"given":"Rosanna","family":"Smart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushka","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamis","family":"Mohamoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108921_bb0005","series-title":"The opioid crisis and the black\/african american population: an urgent issue","author":"Administration","year":"2020"},{"issue":"1","key":"10.1016\/j.jsat.2022.108921_bb0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19","volume":"173","author":"Alexander","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1016\/j.jsat.2022.108921_bb0015","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1377\/hlthaff.2019.00859","article-title":"In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants","volume":"38","author":"Barnett","year":"2019","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2022.108921_bb0020","first-page":"1","article-title":"Polysubstance use in the US opioid crisis","author":"Compton","year":"2020","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jsat.2022.108921_bb0025","series-title":"Changes in characteristics of opioid overdose death trends during the COVID-19 pandemic. medRxiv","author":"DiGennaro","year":"2021"},{"issue":"2","key":"10.1016\/j.jsat.2022.108921_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2022.108921_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2016.01.013","article-title":"Receipt of pharmacotherapy for opioid use disorder by justice-involved US veterans health administration patients","volume":"160","author":"Finlay","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"34","key":"10.1016\/j.jsat.2022.108921_bb0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","article-title":"Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine\u201425 states, July\u2013December 2017 to January\u2013June 2018","volume":"68","author":"Gladden","year":"2019","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"6","key":"10.1016\/j.jsat.2022.108921_bb0045","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee","year":"2018","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.jsat.2022.108921_bb0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2019.01.031","article-title":"Polydrug use disorders in individuals with opioid use disorder","volume":"198","author":"Hassan","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108921_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108927","article-title":"Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use","volume":"227","author":"Hollander","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2022.108921_bb0060","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/add.14878","article-title":"The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States","volume":"115","author":"Hoots","year":"2020","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jsat.2022.108921_bb0065","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1007\/s11606-020-06339-3","article-title":"Validity of incident opioid use disorder (OUD) diagnoses in administrative data: A chart verification study","volume":"36","author":"Howell","year":"2021","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2022.108921_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0376-8716(01)00120-X","article-title":"Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: Implications for treatment entry","volume":"64","author":"John","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2022.108921_bb0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/epirev\/mxaa011","article-title":"The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms","volume":"42","author":"Jones","year":"2020","journal-title":"Epidemiologic Reviews"},{"issue":"2","key":"10.1016\/j.jsat.2022.108921_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/add.14812","article-title":"Increases in methamphetamine use among heroin treatment admissions in the United States, 2008\u20132017","volume":"115","author":"Jones","year":"2020","journal-title":"Addiction"},{"issue":"17","key":"10.1016\/j.jsat.2022.108921_bb0085","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.jsat.2022.108921_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2017.02.006","article-title":"The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a US national sample","volume":"175","author":"Krawczyk","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"34","key":"10.1016\/j.jsat.2022.108921_bb0095","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.15585\/mmwr.mm6934a1","article-title":"Nonfatal drug and polydrug overdoses treated in emergency departments\u201429 states, 2018\u20132019","volume":"69","author":"Liu","year":"2020","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108921_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2019.106142","article-title":"A latent class analysis of drug and substance use patterns among patients treated in emergency departments for suspected drug overdose","volume":"101","author":"Liu","year":"2020","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2022.108921_bb0105","author":"MACPAC"},{"issue":"5","key":"10.1016\/j.jsat.2022.108921_bb0110","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m10657","article-title":"The three-year course of multiple substance use disorders in the united States: A national longitudinal study","volume":"78","author":"McCabe","year":"2017","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jsat.2022.108921_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","article-title":"Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events?","volume":"105","author":"Meinhofer","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108921_bb0120","article-title":"Continuity of pharmacotherapy for opioid use disorder (OUD)","author":"National Quality Forum","year":"2021","journal-title":"Centers for Medicare & Medicaid Services."},{"key":"10.1016\/j.jsat.2022.108921_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108261","article-title":"Utilization of treatment by medicaid enrollees with opioid use disorder and co-occurring substance use disorders","volume":"217","author":"O\u2019Brien","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108921_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108555","article-title":"Adverse events among adult medicaid enrollees with opioid use disorder and co-occurring substance use disorders","volume":"221","author":"O\u2019Brien","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2022.108921_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/add.14434","article-title":"Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature","volume":"114","author":"O'Donnell","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108921_bb0140","series-title":"The opioid epidemic and Medicaid's role in facilitating access to treatment","author":"Orgera","year":"2019"},{"key":"10.1016\/j.jsat.2022.108921_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108580","article-title":"Shifts in drug seizures in the united States during the COVID-19 pandemic","volume":"221","author":"Palamar","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108921_bb0150","article-title":"Alcohol and other substance use during the COVID-19 pandemic: A systematic review","volume":"109150","author":"Roberts","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2022.108921_bb0155","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1377\/hlthaff.2015.1424","article-title":"Hospitalizations related to opioid abuse\/dependence and associated serious infections increased sharply, 2002\u201312","volume":"35","author":"Ronan","year":"2016","journal-title":"Health Affairs"},{"issue":"7","key":"10.1016\/j.jsat.2022.108921_bb0160","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population","volume":"55","author":"Saloner","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.jsat.2022.108921_bb0165","article-title":"Geographic location of buprenorphine-waivered physicians and integration with health systems","volume":"108034","author":"Saloner","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2022.108921_bb0170","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid: the impact of longer treatment on health care outcomes for opioid use disorder within a key population of medicaid enrollees","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2022.108921_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2022.108921_bb0180","doi-asserted-by":"crossref","first-page":"e205734","DOI":"10.1001\/jamanetworkopen.2020.5734","article-title":"Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts","volume":"3","author":"Schiff","year":"2020","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.jsat.2022.108921_bb0185","doi-asserted-by":"crossref","first-page":"e1649","DOI":"10.1093\/cid\/ciaa1278","article-title":"Evaluating differences in opioid and stimulant use-associated infectious disease hospitalizations in florida, 2016\u20132017","volume":"73","author":"Serota","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1016\/j.jsat.2022.108921_bb0190","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1377\/hlthaff.2019.01041","article-title":"Treatment of opioid use disorder among commercially insured US adults, 2008\u201317: Study examines how medicare rural add-on payments affected the number of home health agencies serving rural counties","volume":"39","author":"Shen","year":"2020","journal-title":"Health Affairs"},{"issue":"12","key":"10.1016\/j.jsat.2022.108921_bb0195","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1016\/j.csda.2005.07.019","article-title":"Robust variance estimation for random effects meta-analysis","volume":"50","author":"Sidik","year":"2006","journal-title":"Computational Statistics & Data Analysis"},{"issue":"1","key":"10.1016\/j.jsat.2022.108921_bb0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.15163","article-title":"Systematic review of the emerging literature on the effectiveness of naloxone access laws in the united states","volume":"116","author":"Smart","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108921_bb0205","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jsat.2022.108921_bb0210","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US medicaid enrollees in 11 states, 2014\u20132018","volume":"326","year":"2021","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jsat.2022.108921_bb0215","article-title":"Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19","volume":"122","author":"Tiako","year":"2021","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222002033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222002033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:57:43Z","timestamp":1760039863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"alternative-id":["S0740547222002033"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108921","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108921"}}